

**20<sup>th</sup> May 2025**

To: Generic Medicines Section  
Centre of Product & Cosmetic Evaluation (PPPK)  
National Pharmaceutical Regulatory Agency  
Lot 36, Jalan Universiti,  
46200 Petaling Jaya  
Selangor, Malaysia  
**Attn: Variation Officer**

Dear Sir/Madam,


**COMMITMENT LETTER FOR BLISTER COLOUR DIFFERENTIATION AS PER NPRA DRGD REQUIREMENT**

|                          |                                                              |
|--------------------------|--------------------------------------------------------------|
| <b>Product Name</b>      | <b>: Neotigason capsules 10mg / Neotigason capsules 25mg</b> |
| <b>Active ingredient</b> | <b>: Acitretin</b>                                           |
| <b>MAL no.</b>           | <b>: MAL21026034ACZ / MAL21026035ACZ</b>                     |
| <b>Reference</b>         | <b>: Variation Codes 106716 / 106719</b>                     |
| <b>Manufacturer</b>      | <b>: Cenexi, Osny, France</b>                                |

Reference to NPRA Quest3+ variation remarks for variation codes 106716 & 106719 dated 19 May 2025 refers.

We herewith commit to complying with the labelling requirements when deemed necessary for the safety of the patients.

Thank you.  
Yours Sincerely,



Jenny Lim  
Mgr, Regulatory Affairs  
[jennylim@dchauriga.com](mailto:jennylim@dchauriga.com)